Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early everolimus initiation and cyclosporine elimination in de novo heart transplant recipients
2009-013074-41Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in post-orthotopic heart transplantation status, coronary vasculopathy and chronic kidney disease (CKD) (2 arms), sponsored by Novartis. Primary endpoints: Measured Glomerular Filtration Rate (mGFR) at week 7–11 and Measured Glomerular Filtration Rate (mGFR) at 12 months. Started Aug 2009; status: completed.
02
Drugs
everolimus
03
Conditions
post-orthotopic heart transplantation statuscoronary vasculopathychronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-013074-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013074-41.